Gastrointestinal Stromal Tumor Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examine DelveInsight | Novartis, Cogent Biosciences, Plexxikon, Ariad Pharma, Exelixis

Posted on
by

Gastrointestinal Stromal Tumor Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examine DelveInsight | Novartis, Cogent Biosciences, Plexxikon, Ariad Pharma, Exelixis
DelveInsight’s “Gastrointestinal Stromal Tumor Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Gastrointestinal Stromal Tumor, historical and forecasted epidemiology as well as the Gastrointestinal Stromal Tumor market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

DelveInsight’s “Gastrointestinal Stromal Tumor Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Gastrointestinal Stromal Tumor, historical and forecasted epidemiology as well as the Gastrointestinal Stromal Tumor market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Gastrointestinal Stromal Tumor market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Gastrointestinal Stromal Tumor Market Forecast

 

Some of the key facts of the Gastrointestinal Stromal Tumor Market Report: 

  • The Gastrointestinal Stromal Tumor market size was valued approximately USD 454 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • According to DelveInsight’s analysis, 15,140 GIST event instances are expected to occur overall in the 7MM by the year 2022. The US had the highest incident GIST cases in 2022 (6,528 instances), and this number is predicted to climb sharply in the near future due to improvements in diagnostic tests and genetic testing
  • Based on mutation, the total incidence cases of GIST are divided into KIT mutation, PDGFRA mutation, BRAF mutation, and others. According to the evaluation, there will be 11,961 incident cases of KIT mutation, 1,629 incident cases of PDGFRA mutation, 137 incident cases of BRAF mutation, and 1,413 incident cases of other mutation in the 7MM in 2022
  • There were 3,967 incident cases in the localized stage, 979 in the regional stage, 1,306 in the remote stage, and 276 in the unknown stage in the US in 2022, it was discovered
  • Germany had the biggest incident population of GIST among the European nations in 2022, with 1,787 cases, followed by Italy with 1,162 instances. Spain, however, had the lowest occurrence rate (920 cases)
  • In our analysis, we determined that, in the US in 2022, the population of age groups 51 to 65 years was expected to have the highest number of GIST cases (2,363 cases), followed by 66 to 80 years (1,965 cases)
  • Key Gastrointestinal Stromal Tumor Companies: Taiho Pharmaceutical, Cogent Biosciences, Inc./ Plexxikon, Ariad Pharmaceuticals, Exelixis, Theseus Pharmaceutical, Jiangsu Hengrui Medicine, Cogent Biosciences, Novartis, Ascentage Pharma Group, Daiichi Sankyo Company, IDRx, Inc., and others
  • Key Gastrointestinal Stromal Tumor Therapies: TAS-116, Bezuclastinib, Iclusig, Cabozantinib, THE-630, Famitinib, PLX9486, Nilotinib, HQP1351, DS 6157, IDRX-42, and others
  • The Gastrointestinal Stromal Tumor epidemiology based on gender analyzed that males accounted for a larger proportion of about 52% of total incident cases.
  • The Gastrointestinal Stromal Tumor market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gastrointestinal Stromal Tumor pipeline products will significantly revolutionize the Gastrointestinal Stromal Tumor market dynamics.

 

Gastrointestinal Stromal Tumor Overview

Gastrointestinal stromal tumor (GIST) is an uncommon kind of cancer that affects the digestive tract or adjacent structures in the abdomen, according to GIST Support International. Interstitial cells of Cajal (ICCs) or less differentiated stem cells or precursor cells that can grow into ICCs are the sources of this sarcoma.

 

Get a Free sample for the Gastrointestinal Stromal Tumor Market Report 

https://www.delveinsight.com/report-store/gastrointestinal-stromal-tumor-gist-market

 

Gastrointestinal Stromal Tumor Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Gastrointestinal Stromal Tumor Epidemiology Segmentation:

The Gastrointestinal Stromal Tumor market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Gastrointestinal Stromal Tumor
  • Prevalent Cases of Gastrointestinal Stromal Tumor by severity
  • Gender-specific Prevalence of Gastrointestinal Stromal Tumor
  • Diagnosed Cases of Episodic and Chronic Gastrointestinal Stromal Tumor

 

Download the report to understand which factors are driving Gastrointestinal Stromal Tumor epidemiology trends @ Gastrointestinal Stromal Tumor Epidemiology Forecast

 

Gastrointestinal Stromal Tumor Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gastrointestinal Stromal Tumor market or expected to get launched during the study period. The analysis covers Gastrointestinal Stromal Tumor market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Gastrointestinal Stromal Tumor Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Gastrointestinal Stromal Tumor Therapies and Key Companies

  • TAS-116: Taiho Pharmaceutical
  • Bezuclastinib: Cogent Biosciences, Inc./ Plexxikon
  • Iclusig: Ariad Pharmaceuticals
  • Cabozantinib: Exelixis
  • THE-630: Theseus Pharmaceutical
  • Famitinib: Jiangsu Hengrui Medicine
  • PLX9486: Cogent Biosciences
  • Nilotinib: Novartis
  • HQP1351: Ascentage Pharma Group
  • DS 6157: Daiichi Sankyo Company
  • IDRX-42: IDRx, Inc.

 

Discover more about therapies set to grab major Gastrointestinal Stromal Tumor market share @ Gastrointestinal Stromal Tumor Treatment Market

 

Gastrointestinal Stromal Tumor Market Drivers

  • Rich emerging Gastrointestinal Stromal Tumor pipeline
  • Increasing incidence
  • Understanding of pathophysiology
  • Increased awareness
  • Identification of solid tumor’s treatment with NTRK gene fusions

 

Gastrointestinal Stromal Tumor Market Barriers

  • Resistance against pharmacological therapies
  • Clinical challenges in the management of disease
  • High economic burden
  • Side effects and adverse events after treatment

 

Scope of the Gastrointestinal Stromal Tumor Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Gastrointestinal Stromal Tumor Companies: Taiho Pharmaceutical, Cogent Biosciences, Inc./ Plexxikon, Ariad Pharmaceuticals, Exelixis, Theseus Pharmaceutical, Jiangsu Hengrui Medicine, Cogent Biosciences, Novartis, Ascentage Pharma Group, Daiichi Sankyo Company, IDRx, Inc., and others
  • Key Gastrointestinal Stromal Tumor Therapies: TAS-116, Bezuclastinib, Iclusig, Cabozantinib, THE-630, Famitinib, PLX9486, Nilotinib, HQP1351, DS 6157, IDRX-42, and others
  • Gastrointestinal Stromal Tumor Therapeutic Assessment: Gastrointestinal Stromal Tumor current marketed and Gastrointestinal Stromal Tumor emerging therapies
  • Gastrointestinal Stromal Tumor Market Dynamics: Gastrointestinal Stromal Tumor market drivers and Gastrointestinal Stromal Tumor market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Gastrointestinal Stromal Tumor Unmet Needs, KOL’s views, Analyst’s views, Gastrointestinal Stromal Tumor Market Access and Reimbursement 

 

To know more about Gastrointestinal Stromal Tumor companies working in the treatment market, visit @ Gastrointestinal Stromal Tumor Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Gastrointestinal Stromal Tumor Market Report Introduction

2. Executive Summary for Gastrointestinal Stromal Tumor

3. SWOT analysis of Gastrointestinal Stromal Tumor

4. Gastrointestinal Stromal Tumor Patient Share (%) Overview at a Glance

5. Gastrointestinal Stromal Tumor Market Overview at a Glance

6. Gastrointestinal Stromal Tumor Disease Background and Overview

7. Gastrointestinal Stromal Tumor Epidemiology and Patient Population

8. Country-Specific Patient Population of Gastrointestinal Stromal Tumor 

9. Gastrointestinal Stromal Tumor Current Treatment and Medical Practices

10. Gastrointestinal Stromal Tumor Unmet Needs

11. Gastrointestinal Stromal Tumor Emerging Therapies

12. Gastrointestinal Stromal Tumor Market Outlook

13. Country-Wise Gastrointestinal Stromal Tumor Market Analysis (2019–2032)

14. Gastrointestinal Stromal Tumor Market Access and Reimbursement of Therapies

15. Gastrointestinal Stromal Tumor Market Drivers

16. Gastrointestinal Stromal Tumor Market Barriers

17.  Gastrointestinal Stromal Tumor Appendix

18. Gastrointestinal Stromal Tumor Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services